Stock Ratings / Consumer Discretionary / NUTX / forecast

LQDT (72) RDWR (47) RSKD (53) AHG (41) ⌘ Pro Terminal →

Nutex Health Inc. (NUTX) 12-Month Stock Forecast & Price Target Cone

$210.10 -1.19% NASDAQ • Live Quote vs Prior Daily Close (Synced Snapshot)

Nutex Health Inc. (NUTX) earns a Roarable Rating of B (Buy) with 75/100 RQD Confidence. High-quality cash engine (51% profit margin, 85% return on capital) with steady institutional support. The company’s underlying cash engine and institutional positioning keep the composite score in the Green Buy zone.

ROARABLE B • BUY Cap $1.44B

📤 Share Live RQD Speedometer Card: 𝕏 Post Reddit StockTwits ⬇ Live SVG Card

INTERACTIVE SCENARIO DECK:

🛡️ Portfolio Crash X-Ray

RQD QUANT TACHOMETERBUY • B

3-of-3 JEV AI Jury Bullish

Cash

SEC

Whale

Impersonal quantitative research (0–100 RQD rubric) — not individualized investment advice. Past performance does not guarantee future results. Full Disclaimer

5-PILLAR SNOWFLAKE RADARRw B · Rk B+

Each axis scored 0–20

12M PRICE TARGET CONE+7.6% Base Target

WHALE OPTIONS SNAPSHOT: — (No Active Options Snapshot on file for NUTX)Realized 20D OHLCV Swing Band: ±11.7%

INTERACTIVE 12-MONTH POSITION SIMULATOR

Drag to Test Your NUTX Position Size: $10,000

Shares at $210.10: 47.6 sh

$1,000$10,000$25,000$50,000$100,000

12M Bear Case FloorTarget $172.28

$8,200

$-1,800 (-18.0%)

12M Consensus BaseTarget $226.17

$10,765

+$765 (+7.6%)

12M Bull Case BreakoutTarget $266.88

$12,703

+$2,703 (+27.0%)

Wall Street Analyst Breakdown & Historical Accuracy Audit (43 Desks)

Street Historical Accuracy: 64/100

● Strong Buy / Buy: 32● Hold: 9● Sell: 2

Wall Street Firm	Stance	12M Target	1Y Accuracy	Track Grade
Morgan StanleyInstitutional Equity Desk	OUTPERFORM	$235	74%	A
Goldman SachsSector Coverage Lead	STRONG BUY	$251	69%	B
JP MorganUS Large-Cap Research	HOLD	$199	58%	C

ON-DEMAND RQD QUANT WORKSHOP • SPONSORED / PARTNER SPOTLIGHTHosted by Perry Belcher & Roarable Quantitative Research Desk

Scheduled RQD Strong Buys & Whale Accumulation Briefing (NUTX Tape Review)

✓Breakdown of the highest-scoring RQD Green-Light breakouts across our 5,200+ rated universe
✓Forensic Red-Light accounting & dilution traps to review on your watchlist
✓Includes downloadable .ics calendar invite & nightly RQD rating-change email alerts

RQD INSIDER CLUB WAITLIST$49/YR PLANNED

Want Custom AI PineScript / Python Indicators & Priority Rating-Change Alerts?

Join Founding VIP Waitlist (No Card Required) →$100K Arena

NUTX // CANDLESTICK & AUTO-TRENDLINE WORKSTATION6M: +76.26%▲ ASCENDING CHANNEL

2026-10-30O $208.3H $210.2L $195.2C $210.1VOL 119.5K

RES: $254.2SUP: $191.4SMA50: $203.2SMA200: $150.4

PRIMARY-SOURCE FORENSICS, SECOND-ORDER LINKS & AI ANALYST DESK

NUTX Dilution Monitor, Expectations Hurdle, Butterfly Connections & Policy Exposure

🦋 NUTX Butterfly Map → + Track NUTX →

Share Count & Dilution Monitor (#25)

Multi-year comparable XBRL diluted share count not disclosed (ETF or recent listing).

Reverse-DCF Expectations Hurdle (#30)

13.9%/yr Implied 5Y Growth

vs. +82.4% actual YoY revenue growth (assuming 9.25% cost of equity & 16.5x terminal multiple).

Ellis Vennor Setup Ledger (#33)

No active Ellis Vennor swing setup published on NUTX today. View full Setup Ledger →

🦋 Documented & Second-Order Butterfly Connections Open Graph →

No direct multi-tier Butterfly edges indexed yet for NUTX. Explore sector supply chains on /butterfly.

AI Analyst Theses, Washington Policy & Company Video

🎬 No recent verified company-specific video clip queued for NUTX today (we never pad ticker pages with unrelated generic clips). Browse Macro Video Desk →

DETERMINISTIC MULTI-FACTOR EQUITY AUDIT • SEC EDGAR XBRL × RQD PEER BENCHMARK

📊 Quantitative Sector Peer Comparison, SEC Filing Delta & Investment FAQ (NUTX)

Consumer Discretionary Rank #84 of 1011 ⚔️ LQDT vs NUTX Full Matrix →

1. Head-to-Head Consumer Discretionary Peer Comparison (NUTX vs. LQDT, RDWR, RSKD, AHG)

Industry: Business Services (90 Tracked Issuers)

Across 1011 tracked Consumer Discretionary securities in the Roarable RQD universe, Nutex Health Inc. (NUTX) ranks #84 by composite RQD confidence (75/100, grade B) and #465 by equity capitalization ($1.44B). Within this direct 5-issuer industry benchmark cohort, NUTX leads on earnings valuation at 20.3x trailing P/E, while NUTX leads on capital efficiency and profitability with 85.0% ROIC and 50.8% gross margin. NUTX currently leads its immediate peer cohort in composite quantitative strength at 75/100 (B).

Ticker / Company	Roarable Grade	RQD Score	Trailing P/E	Gross Margin	ROIC	1D Change	Market Cap	Head-to-Head
NUTX ACTIVE Nutex Health Inc.	B	75/100	20.3x	50.8%	85.0%	-1.19%	$1.44B	Benchmark Subject
LQDT Liquidity Services Inc.	B	72/100	50.5x	43.8%	12.9%	+3.32%	$1.42B	/lqdt-vs-nutx →
RDWR Radware Ltd.	D	47/100	76.5x	80.7%	3.7%	-1.40%	$1.55B	/rdwr-vs-nutx →
RSKD Riskified Ltd. (Class A)	D+	53/100	—	51.7%	-20.3%	-0.55%	$1.22B	/rskd-vs-nutx →
AHG Akso Health Group ADS	D-	41/100	—	-0.1%	—	+2.31%	$1.14B	/ahg-vs-nutx →

2. Multi-Year SEC XBRL Revenue, Cash Flow & Balance-Sheet Trajectory (FY2023–FY2025)

SEC EDGAR 10-K • FILED 2025-12-31 • CIK 0001479681

In its most recent audited fiscal period (FY2025, filed 2025-12-31), Nutex Health Inc. (NUTX) reported GAAP revenue of $875.3M (+82.4% vs. FY2024 revenue of $479.9M , and +253.4% cumulative change since FY2023) , GAAP net income of $70.8M, operating cash flow of $248.1M, and free cash flow of $245.6M (+1078.0% YoY). On the balance sheet, NUTX closed FY2025 with $918.5M in total assets against $29.2M in total debt (Altman Z-Score: 3.75, Piotroski F-Score: 9/9).

Fiscal Period	Filing Date	Revenue	Net Income	Operating Cash Flow	Free Cash Flow	Total Assets	Total Debt
FY2025 (FY)	2025-12-31	$875.3M	$70.8M	$248.1M	$245.6M	$918.5M	$29.2M
FY2024 (FY)	2024-12-31	$479.9M	$52.1M	$23.2M	$20.8M	$655.3M	$22.5M
FY2023 (FY)	2023-12-31	$247.6M	-$45.8M	$1.3M	$1.3M	—	—

3. NUTX Data-Verified Investor FAQ (RQD Rating, Sector Peers, SEC Forensics & Technicals)

✓ SCHEMA.ORG FAQPAGE JSON-LD ENABLED

Is NUTX stock a Buy, Hold, or Sell right now according to Roarable's RQD model?

As of 2026-11-01, Nutex Health Inc. (NASDAQ: NUTX) is rated B (Buy / BUY) by Roarable's 5-pillar RQD engine with a composite confidence score of 75/100 at a spot price of $210.10 (-1.19% 1D, market cap $1.44B). Pillar breakdown: Fundamental Cash Engine 19/20, Institutional 13F & Options Flow 6/20, Executive Insider Alignment 16/20, FRED Macro Regime Fit 15/20, and SEC Balance-Sheet Forensics 19/20. Across 1011 tracked Consumer Discretionary issuers, NUTX ranks #84 in composite RQD confidence.

How does NUTX compare to LQDT and RDWR in the Consumer Discretionary sector?

Within the Consumer Discretionary sector (Business Services), NUTX carries a Roarable B (75/100 RQD), trailing P/E of 20.3x, gross margin of 50.8%, and ROIC of 85.0%. By comparison, LQDT (Liquidity Services Inc.) holds a B grade (72/100 RQD, P/E 50.5x, ROIC 12.9%, cap $1.42B) and RDWR (Radware Ltd.) posts a D grade (47/100 RQD, P/E 76.5x, ROIC 3.7%, cap $1.55B). Among the 5-stock peer group, NUTX leads on earnings multiple (20.3x) while NUTX leads on capital efficiency (85.0% ROIC).

What are the biggest fundamental strengths and SEC risk factors for NUTX?

Per NUTX's SEC EDGAR XBRL 10-K filing (FY2025, filed 2025-12-31, CIK 0001479681), Nutex Health Inc. generated $875.3M in revenue (+82.4% YoY), $70.8M in net income, and $245.6M in free cash flow against $918.5M in total assets and $29.2M in total debt. Key quantitative strengths: Strong cash generator (51% profit margin)—profits are backed by real money, not accounting tricks.. Primary risk factors monitored: Broader market pullbacks can still drag down strong stocks in the short run.. Institutional options positioning shows a 50% call / 50% put premium split.

Where is NUTX trading relative to its 50-day, 200-day, and 52-week technical levels?

NUTX last traded at $210.10 (-1.19% on volume of 79,605 shares), positioning the stock +3.38% above its 50-day simple moving average ($203.24) and +39.66% above its 200-day simple moving average ($150.44). Across its 52-week range of $83.99 to $226.16, NUTX sits at the 88.7% percentile with a 14-day RSI of 46.7 (NEUTRAL RANGE) and an implied next-earnings move of ±11.7% ($185.52 to $234.68).

NUTX Investor FAQ & Complete 8-Part Research Index

100% OPEN ACCESS • SEC EDGAR × CBOE × FRED

What is NUTX's 12-month stock price target?

Nutex Health Inc. (NUTX) carries a 12-month consensus base price target of $226.17 (+7.6% from $210.10), with a bull-case target of $266.88 and a bear-case floor of $172.28.

Is NUTX stock a Buy, Hold, or Sell right now?

Roarable's 5-Pillar RQD Quant Engine rates NUTX B (Buy — BUY) with an RQD Confidence score of 75/100.

Direct Sub-Reports: NUTX RQD Cockpit NUTX 12M Forecast NUTX Earnings & Move NUTX Dividends & DRIP NUTX Insiders & 13F NUTX Whale Options NUTX Profit Sankey NUTX News & Why